Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
Hyeok‐Hee Lee, Han Ah Lee, Eun-Jin Kim, et al.
Gut (2023), pp. gutjnl-331003
Closed Access | Times Cited: 80

Showing 1-25 of 80 citing articles:

MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2024), pp. gutjnl-330595
Open Access | Times Cited: 220
Steatotic liver disease
Mads Israelsen, Sven Francque, Emmanuel Tsochatzis, et al.
The Lancet (2024) Vol. 404, Iss. 10464, pp. 1761-1778
Closed Access | Times Cited: 24
Impact of MASLD and MetALD on clinical outcomes: A meta‐analysis of preliminary evidence
Stefano Ciardullo, Alessandro Mantovani, Mario Luca Morieri, et al.
Liver International (2024) Vol. 44, Iss. 8, pp. 1762-1767
Closed Access | Times Cited: 15
Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease
Niki Katsiki, Genovefa Kolovou, Michal Vráblík
Current Cardiology Reports (2025) Vol. 27, Iss. 1
Closed Access | Times Cited: 1
Correlation between metabolic dysfunction-associated steatotic liver disease and subclinical coronary atherosclerosis in eastern China
Guanghui Ma, Guohou Xu, Haixia Huang
Diabetology & Metabolic Syndrome (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 1
Prevalence of Steatotic Liver Disease Based on a New Nomenclature in the Japanese Population: A Health Checkup-Based Cross-Sectional Study
Takao Miwa, Satoko Tajirika, Nanako Imamura, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 4, pp. 1158-1158
Open Access | Times Cited: 12
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
Haixiang Zheng, Leonardo A. Sechi, Eliano Pio Navarese, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 11
Systemic metabolic abnormalities: Key drivers of complications and mortality in MASLD
Xiude Fan, Bofei Zhang, Yingzhou Shi, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 6, pp. e246-e248
Open Access | Times Cited: 9
Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia
Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, et al.
Clinical and Molecular Hepatology (2024) Vol. 30, Iss. 3, pp. 577-579
Open Access | Times Cited: 9
The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis
Qiong Lv, Hua-Shan Zhao
Annals of Medicine (2024) Vol. 56, Iss. 1
Open Access | Times Cited: 8
New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice
Clémence M. Canivet, Jérôme Boursier, Rohit Loomba
Seminars in Liver Disease (2024) Vol. 44, Iss. 01, pp. 035-042
Closed Access | Times Cited: 8
ZBP1-mediated apoptosis and inflammation exacerbate steatotic liver ischemia-reperfusion injury
Yizhi Liu, Huan Cao, Shu‐Hua Zhang, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 13
Open Access | Times Cited: 8
Liver cancer risk across metabolic dysfunction-associated steatotic liver disease and/or alcohol: a nationwide study
Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, et al.
The American Journal of Gastroenterology (2024)
Closed Access | Times Cited: 8
Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis
Renuka Suvarna, Sahana Shetty, Joseph M. Pappachan
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 7
Diagnostic Performance of Noninvasive Tests in Patients with MetALD in a Health Check-up Cohort
Joo Hyun Oh, Sang Bong Ahn, Seon Cho, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 7
Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis
Marc Gurun, Paul Brennan, Sava Handjiev, et al.
PLoS ONE (2024) Vol. 19, Iss. 4, pp. e0299507-e0299507
Open Access | Times Cited: 6
Lipid Nanoparticle‐Mediated Delivery of CRISPR‐Cas9 Against Rubicon Ameliorates NAFLD by Modulating CD36 Along with Glycerophospholipid Metabolism
Yu Bai, Yanyang Nan, Tao Wu, et al.
Advanced Science (2024) Vol. 11, Iss. 31
Open Access | Times Cited: 6
Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences
Joo Hyun Oh, Dae Won Jun
Clinical and Molecular Hepatology (2024) Vol. 30, Iss. 2, pp. 168-170
Open Access | Times Cited: 5
Platelet, Antiplatelet Therapy and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review
Andrea Boccatonda, Lorenza Del Cane, Lara Marola, et al.
Life (2024) Vol. 14, Iss. 4, pp. 473-473
Open Access | Times Cited: 5
Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Amani Elshaer, David M. Chascsa, Blanca Lizaola‐Mayo
Life (2024) Vol. 14, Iss. 7, pp. 844-844
Open Access | Times Cited: 5
Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
Yewan Park, Jooyi Jung, Seungbong Han, et al.
Alimentary Pharmacology & Therapeutics (2024)
Open Access | Times Cited: 5
Association of changes in the type 2 diabetes and MASLD/related SLD status with risk of developing cardiovascular disease
Yasuhiro Matsubayashi, Kazuya Fujihara, LAY MON KHIN, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Remnant cholesterol and its variability independent of low density lipoprotein cholesterol predict metabolic dysfunction associated steatotic liver disease
Yuting Sun, Xinlei Miao, Manling Hu, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Metabolic dysfunction-associated steatotic liver disease increases cardiovascular disease risk in young adults
Goh Eun Chung, Su Jong Yu, Jeong‐Ju Yoo, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Revolutionizing MASLD: How Artificial Intelligence Is Shaping the Future of Liver Care
Nicola Pugliese, Arianna Bertazzoni, Cesare Hassan, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 722-722
Open Access
Page 1 - Next Page

Scroll to top